Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Abstract

Objective. To compare tumor necrosis factor ␣ inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.Methods. The nationwide DANBIO registry collects data on rheumatology patients receiving routine care. For the present study, we included patients from DANBIO who had RA (n ‫؍‬ 2,326) in whom the first biologic treatment was initiated (29% received adalimumab, 22% received etanercept, and 49% received infliximab). Baseline predictors of treatment response were identified. The odds ratios (ORs) for clinical responses and remission and hazard ratios (HRs) for drug withdrawal were calculated, corrected for age, disease duration, the Disease Activity Score in 28 joints

Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial

“…Patients with an inadequate response to MTX frequently progress to receive biologic DMARDs, including tumor necrosis factor inhibitors (TNFi). However, many patients do not respond well, lose their clinical response, or experience adverse events with TNFi (11)(12)(13)(14). Although patients with an inadequate response to one TNFi may be switched to a second TNFi, patients may experience progressive loss of efficacy with a subsequent TNFi (15).…”

Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study

“…16 Older age, low functional status, and concomitant prednisolone treatment have been suggested as negative predictors of a clinical response and remission. 17 Our results demonstrated that 58% (n=11) of the patients receiving bDMARDs had MDA or HDA status. These patients in the MDA/HDA subgroup did not exhibit differences from those receiving bDMARDs in remission/LDA subgroup in terms of age and concomitant glucocorticoid use.…”

TNF Inhibitor Therapy for Rheumatoid Arthritis

“…Total efficacies of varying biologics are highly similar, which have been observed in most of the studies and adopted by several investigators (55). Nevertheless, a recent study indicated significant differences in the efficacy of and adherence to therapy with ADA, ETN and IFX (56). IFX had the lowest treatment responses, disease remission and drug adherence rates.…”